Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Gilead and Terray Therapeutics Enter Strategic Collaboration for Novel Small Molecule Therapies

Dec 18, 2024•over 1 year ago

Contract Type

partnership

Foster CityBiotechnologyHealth CareTherapeuticsBiopharma

Description

Gilead and Terray Therapeutics have announced a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray's tNova platform, which integrates high-throughput chemical experimentation and AI-driven drug discovery, will be utilized to discover and develop small molecule compounds against selected targets by Gilead. Terray will receive upfront payment, milestone payments, and tiered royalties on net sales of products commercialized by Gilead. As a result of this collaboration, Gilead's GAAP and non-GAAP 2024 EPS are expected to reduce by approximately 1c.

Company Information

Company

Gilead Sciences

Location

Foster City, California, United States

About

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Gilead Sciences's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.